Sentences with phrase «based products liability litigation»

acted as Liaison Counsel in In re: Oral Sodium Phosphate Solution - Based Products Liability Litigation, MDL No. 2066 (Northern District of Ohio, Eastern Division) which resulted in a substantial confidential settlement on behalf of hundreds of individual claimants.

Not exact matches

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Second, and most important, motor vehicle litigation will move from a system where accidents are assessed based on driver negligence to a products liability system, where manufacturers bear more of the burden for failure of things such as sensors and warning systems.

Brendan has acted on a wide range of insurance and reinsurance matters for Australian - based and international clients, including flooding, storm, earthquake, fire and explosion events, electricity supply issues and machinery break - downs, as well as high - value class action litigation, public and product liability, and subrogation claims.

Based in Bloomfield Hills, Michigan, Wolfe concentrates his practice on discovery and e-discovery issues, as well as on class actions and product liability litigation.

The team, which focuses on product liability work and tobacco litigation specifically, comprises five New York - based partners, including Chadbourne's litigation head, Thomas Riley.

Brian Brown manages, supervises and handles the defense litigation cases involving automobile negligence, products liability, premises liability including lead - based paint poisoning, civil assaults, construction accidents, insurance coverage, insurance fraud and claims of negligent security, including ATMs.

He currently serves as co-lead counsel in the In re: Gadolinium Based Contrast Agent Litigation, which is pending in the U.S. District Court for the Northern District of Ohio; the Plaintiff's Executive Committee in the In re: Abilify Products Liability Litigation pending in the U.S. District Court for the Northern District of Florida; the Plaintiff's Executive Committee in the In re: Benicar Products Liability Litigation pending in the U.S. District Court for the District of New Jersey; the Plaintiff's Steering Committee in the In re: Actos (Pioglitazone) Products Liability Litigation pending in the U.S. District Court for the Western District of Louisiana; and the Plaintiff's Steering Committee in the In re: Fresenius Granuflo / Naturalyte Dialysate Products Liability Litigation pending in the U.S. District Court for the District of Massachusetts.

Firm attorneys Aaryn K. Giblin and Colin D. Moore earned selection based on their work in plaintiffs» product liability litigation.

Moderator, «Chief Litigation Counsel Roundtable: Proactively Spotting Litigation Red Flags Based on Current Hot Button Issues in Product Liability,» American Conference Institute Drug and Medical Device Litigation, December 2014

Read our Product Liability Litigation eNewsletter to keep abreast of current legal issues that impact both public and private companies on a local, regional and global basis.

These included chairing Plaintiffs» Discovery Committees for In Re: Vioxx, In Re: Gadolinium - Based Contrast Agent Litigation, MDL 1909 (N.D. Ohio); In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436 (E.D. Pa) and In Re: Rezulin Product Liability Litigation, MDL 1348 (S.D. N.Y).

New York - based litigator William Ruskin, a member of AmLaw 200 firm Epstein Becker Green «s Litigation, Real Estate, and Health Care and Life Sciences practices, blogs at the Toxic Tort Litigation Blog about news and trends in products liability and toxic tort actions.

Based in Calgary, Bruce primarily focuses his practice on all areas of insurance, including insurance corporate / regulatory law, products liability, class actions, transportation, and oil & gas litigation.

The Drug and Medical Device Product Liability Deskbook includes: detailed coverage of: warning - related claims and defenses; other information - based theories; strict liability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanLiability Deskbook includes: detailed coverage of: warning - related claims and defenses; other information - based theories; strict liability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other important topics.

Based in Annapolis, Maryland, our law practice primarily focuses on professional liability litigation, product liability litigation, environmental litigation and all aspects of civil and criminal defense litigation, and many more.

Professional Duties & Responsibilities Designed and installed varied residential and commercial alternative energy technologies Developed wind, solar thermal, and photovoltaic energy - based systems for multiple uses and users Responsible for cold region engineering including ice breaker technology and the Alaskan Pipeline Created and implemented mechanical engineering projects in the field of aerospace technology Designed, constructed, and oversaw operations of 100 ton gold refinery Committed to alternative energy, ecology, and cost - saving energy efficiency Significant mediation and litigation experience focused on alternative energy issues Served as intellectual property, patent, trademark, and products liability attorney University - level lecturer in business, First Amendment law, social responsibility, and ethics